TY - JOUR
T1 - OX40 agonists for cancer treatment
T2 - a patent review
AU - Cebada, Jorge
AU - Perez-Santos, Martin
AU - Bandala, Cindy
AU - Lara-Padilla, Eleazar
AU - Herrera-Camacho, Irma
AU - Rosas-Murrieta, Nora Hilda
AU - Millán-Pérez Peña, Lourdes
AU - Monjaraz, Eduardo
AU - Flores, Amira
AU - Anaya-Ruiz, Maricruz
N1 - Publisher Copyright:
© 2020 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - Introduction: OX40 is an immune checkpoint in cancer and its presence in cancer is a good prognosis, making it a highly relevant target for the development of new immunotherapies. Areas covered: The patent literature reveals vital information on new trends in cancer therapies. The authors used the patent databases of the six major patent offices in the world: United States Patent and Trademark Office, European Patent Office, World Intellectual Property Organization, Japan Patent Office, State Office of Intellectual Property of China and Korean Intellectual Property Office, to generate a panorama of patents related to OX40 agonists. Specific patents have been grouped into innovative patents and adoption patents. Expert opinion: An increasing trend in the development of OX40 agonists in cancer, particularly in the years 2018 and 2019. United States was the leader in generating patents, followed by China and England. Major pharmaceutical companies have at least one anti-OX40 agonist, MEDI6469 and MEDI-0562 (AstraZeneca), PF-04518600 (Pfizer), GSK3174998 (GlaxoSmithKline), BMS-986,178 (Bristol-Myers Squibb) and MOXR0916 (Roche), which represent 68% of clinical trials conducted with OX40 agonists.
AB - Introduction: OX40 is an immune checkpoint in cancer and its presence in cancer is a good prognosis, making it a highly relevant target for the development of new immunotherapies. Areas covered: The patent literature reveals vital information on new trends in cancer therapies. The authors used the patent databases of the six major patent offices in the world: United States Patent and Trademark Office, European Patent Office, World Intellectual Property Organization, Japan Patent Office, State Office of Intellectual Property of China and Korean Intellectual Property Office, to generate a panorama of patents related to OX40 agonists. Specific patents have been grouped into innovative patents and adoption patents. Expert opinion: An increasing trend in the development of OX40 agonists in cancer, particularly in the years 2018 and 2019. United States was the leader in generating patents, followed by China and England. Major pharmaceutical companies have at least one anti-OX40 agonist, MEDI6469 and MEDI-0562 (AstraZeneca), PF-04518600 (Pfizer), GSK3174998 (GlaxoSmithKline), BMS-986,178 (Bristol-Myers Squibb) and MOXR0916 (Roche), which represent 68% of clinical trials conducted with OX40 agonists.
KW - OX40
KW - cancer
KW - immunotherapy
KW - patent
UR - http://www.scopus.com/inward/record.url?scp=85092118088&partnerID=8YFLogxK
U2 - 10.1080/13543776.2021.1825688
DO - 10.1080/13543776.2021.1825688
M3 - Artículo de revisión
C2 - 32945223
AN - SCOPUS:85092118088
SN - 1354-3776
VL - 31
SP - 81
EP - 90
JO - Expert Opinion on Therapeutic Patents
JF - Expert Opinion on Therapeutic Patents
IS - 1
ER -